Immune Checkpoints Beyond PD-1 Series

On the mechanism of anti-CD39 immune checkpoint therapy
David Allard, Bertrand Allard, John Stagg

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000186; DOI: 10.1136/jitc-2019-000186
Master protocols in immuno-oncology: do novel drugs deserve novel designs?
Luca Mazzarella, Stefania Morganti, Antonio Marra, Dario Trapani, Giulia Tini, Piergiuseppe Pelicci, Giuseppe Curigliano

Journal for ImmunoTherapy of Cancer Mar 2020, 8 (1) e000475; DOI: 10.1136/jitc-2019-000475
Lifting the innate immune barriers to antitumor immunity
Carla V Rothlin, Sourav Ghosh

Journal for ImmunoTherapy of Cancer Apr 2020, 8 (1) e000695; DOI: 10.1136/jitc-2020-000695
Tim-3 finds its place in the cancer immunotherapy landscape
Nandini Acharya, Catherine Sabatos-Peyton, Ana Carrizosa Anderson

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000911; DOI: 10.1136/jitc-2020-000911
Monalizumab: inhibiting the novel immune checkpoint NKG2A
Thorbald van Hall, Pascale André, Amir Horowitz, Dan Fu Ruan, Linda Borst, Robert Zerbib, Emilie Narni-Mancinelli, Sjoerd H. van der Burg, Eric Vivier

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 263; DOI: 10.1186/s40425-019-0761-3
LAG-3: from molecular functions to clinical applications
Takumi Maruhashi, Daisuke Sugiura, Il-mi Okazaki, Taku Okazaki

Journal for ImmunoTherapy of Cancer Sep 2020, 8 (2) e001014; DOI: 10.1136/jitc-2020-001014
TIGIT in cancer immunotherapy
Joe-Marc Chauvin, Hassane M Zarour

Journal for ImmunoTherapy of Cancer Sep 2020, 8 (2) e000957; DOI: 10.1136/jitc-2020-000957
Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy
Christopher A Chuckran, Chang Liu, Tullia C Bruno, Creg J Workman, Dario AA Vignali

Journal for ImmunoTherapy of Cancer Jul 2020, 8 (2) e000967; DOI: 10.1136/jitc-2020-000967

Log in using your username and password

Main menu

Log in using your username and password

You are here

Immune Checkpoints Beyond PD-1 Series